Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Taha Nisar

Neurology Mobile, AL Medical Doctor

NPI 1952785263 CMS profile 11341929

1601 Center St, Ste 2E, Mobile, AL 36604

Open in the dashboard

General payments

$1,434

44 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Taha Nisar of Mobile, AL is reported in the CMS Open Payments database as having received $1,434 across 44 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 49th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $777 21
2024 General $198 9
2023 General $175 7
2022 General $284 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Taha Nisar
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Taha Nisar were reported at $777. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Taha Nisar Neurology median Middle half National median
2019 $0 $474 $118–$2,177 $163
2020 $0 $367 $82–$2,309 $114
2021 $0 $438 $104–$2,547 $132
2022 $284 $442 $103–$2,388 $149
2023 $175 $464 $119–$2,312 $160
2024 $198 $468 $119–$2,323 $164
2025 $777 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Medtronic, Inc. $634 15 payments
  2. Stryker Corporation $178 4 payments
  3. Penumbra, Inc. $127 1 payment
  4. Novartis Pharmaceuticals Corporation $51 3 payments
  5. SK Life Science, Inc. $49 2 payments
  6. Janssen Biotech, Inc. $40 2 payments
  7. Argenx US, Inc. $33 1 payment
  8. Genentech USA, Inc. $24 1 payment
  9. CutisPharma, Inc. $24 1 payment
  10. ACADIA Pharmaceuticals Inc $23 1 payment
  11. Other $249 13 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $1,434 44 payments
Products named General payments · program years 2022–2025
  1. Pipeline $538 13 payments
  2. Penumbra Coil 400 $127 1 payment
  3. SURPASS EVOLVE $125 2 payments
  4. SOLITAIRE X $96 2 payments
  5. TREVO $53 2 payments
  6. KESIMPTA $51 3 payments
  7. TARGET $51 2 payments
  8. VYVGART Hytrulo $33 1 payment
  9. NEUROFORM ATLAS $25 1 payment
  10. Ocrevus Zunovo $24 1 payment
  11. Other $338 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

122

Median for Neurology: 833

Drug cost

$18,913

Median for Neurology: $202,670

Branded share of claims

38.5%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 16 $9,424
Brilinta Ticagrelor Brand 17 $8,542
Levetiracetam Generic 30 $410
Amitriptyline Hcl Generic 31 $404
Clopidogrel Clopidogrel Bisulfate Brand 14 $96
Atorvastatin Calcium Generic 14 $37

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$54,786

Medicare's payments for the services billed

Medicare patients

143

Average age 77

Services billed

433

78 women, 65 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Ischemic heart disease 44%
Diabetes 42%
Atrial fibrillation 39%
Chronic kidney disease 36%
Heart failure 29%
Depression 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KESIMPTA
  • Novartis Pharmaceuticals Corporation $38
$38 — —
ZONISADE
  • CutisPharma, Inc. $24
$24 — —
NUPLAZID
  • ACADIA Pharmaceuticals Inc $23
$23 — —
PONVORY
  • Vanda Pharmaceuticals Inc. $22
$22 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

44 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record